BCDA - 200% Gain In One Day - Why Is Heart Failure Focused BioCardia Stock Soaring Today? | Benzinga
The FDA approved BioCardia Inc's (NASDAQ: BCDA) Phase 3 CardiAMP Heart Failure II study protocol of CardiAMP autologous cell therapy for ischemic heart failure.
The currently ongoing CardiAMP Heart Failure trial has completed enrollment, and the final data analyses are anticipated to be reported in Q4 2024.
In an interim analysis of available data to date for study patients followed up through two years, those having N-terminal ...